Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1997
Business Overview: The Company designs, markets, and distributes outdoor footwear, primarily under the Teva(R), Simple(R), and Ugg(R) brands. Operations are seasonal, with Teva(R) sales peaking in the first and second quarters.
Key Financial Metrics
| Metric (Six Months Ended June 30) | 1997 | 1996 |
|---|---|---|
| Net Sales | $62,544,000 | $56,322,000 |
| Gross Profit | $27,482,000 | $23,685,000 |
| Gross Margin | 43.9% | 42.1% |
| Net Earnings | $3,579,000 | $2,503,000 |
| Earnings Per Share (Diluted) | $0.40 | $0.27 |
| Cash from Operations | $12,080,000 | $10,658,000 |
| Cash and Equivalents (End of Period) | $2,277,000 | $6,154,000 |
| Total Debt (Current + Long-term) | $1,341,000 | $10,389,000 |
| Working Capital | $34,606,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.0% year-over-year for the six-month period, driven by a 25.0% increase in Teva(R) sales. This offset an 11.1% decline in Simple(R) sales due to lower demand for specific clog styles.
- Profitability: Net earnings rose 43.0% to $3.579 million. Gross margin improved to 43.9% from 42.1%, attributed to reduced Teva(R) close-outs, the closure of a California manufacturing facility, and lower freight costs.
- Debt Reduction: Long-term debt decreased significantly from $10.29 million to $1.24 million as the Company repaid $9.048 million in notes payable and long-term debt during the period.
- Inventory Management: Inventories decreased 44.3% to $13.887 million, reflecting strong sales volume and reduced stock levels.
- SG&A Expenses: Selling, general, and administrative expenses increased 10.8%, primarily due to legal costs associated with Ugg Holdings disputes and higher royalties on Teva(R) sales.
Guidance, Outlook, and Risks
- Outlook: Management expects Simple(R) sales for the full year 1997 to be flat or lower than 1996. Ugg(R) sales are also expected to be lower than the previous year's $14.8 million. However, these declines are anticipated to be offset by continued growth in the Teva(R) line.
- Liquidity: The Company maintains a $25 million revolving credit facility with approximately $14.2 million available. All borrowings under the facility were repaid as of June 30, 1997.
- Legal Contingencies: Former shareholders of Ugg Holdings have demanded arbitration regarding acquisition payments. The Company disputes these claims but expects substantial legal costs to continue until the arbitration in September 1997.
- Seasonality: Results are highly seasonal. Teva(R) sales peak in Q1/Q2, Simple(R) in Q3, and Ugg(R) in Q4. Consumer preference shifts pose a risk to inventory obsolescence.
- Accounting Changes: The Company will adopt FAS 128 (Earnings per Share) in Q4 1997, requiring dual presentation of Basic and Diluted EPS, though no material impact is expected.
Investor Verification Checklist
- Ugg Arbitration Outcome: Verify the resolution of the arbitration with former Ugg shareholders and the final cost impact on future earnings.
- Simple(R) Product Demand: Monitor Q3 results to confirm if Simple(R) sales stabilize or continue to decline as projected.
- Teva(R) Growth Sustainability: Assess whether the 25% growth in Teva(R) sales can be maintained to offset declines in other product lines.
- Inventory Levels: Confirm that the 44% reduction in inventory does not lead to stockouts during peak seasonal demand.
- Debt Covenant Compliance: Ensure continued compliance with financial ratios required by the revolving credit facility.